Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. ca.linkedin.com › in › jean-louis-stril-a37bb97Jean-Louis Stril - Clinical Research Medical Advisor ...

    View Jean-Louis Stril’s profile on LinkedIn, the world’s largest professional community. Jean-Louis has 6 jobs listed on their profile. See the complete profile on LinkedIn and discover...

    • 255
    • Novartis
    • University of Mexico
    • Dorval, Quebec, Canada

  2. journals.plos.org › plosone › articleThe real world effect of omalizumab add on therapy for ... - PLOS

    9 de ago. de 2020 · Takacsy F, Stril J-L (2017) The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS ONE 12(8): e0183869. https://doi.org/10.1371/journal.pone.0183869 Editor: Heinz Fehrenbach, Forschungszentrum Borstel Leibniz-Zentrum fur Medizin und ...

    • Mohit Bhutani, William H. Yang, Jacques Hébert, Frederica de Takacsy, Jean-Louis Stril
    • 2017

  3. www.researchgate.net › Jean-Louis-Stril-2122468754Jean-Louis Stril's research works | Université du Québec à ...

    Jean-Louis Stril's 4 research works with 55 citations and 145 reads, including: Observed Reduction of Healthcare Utilization after Omalizumab Initiation Among Patients with Persistent...

  4. www.cambridge.org › core › journalsOpen-Label Study of Sleep Disturbances in Patients with ...

    Jean-Louis Stril , Manon Bélanger , Geneviève Lehoux , Donna Coffin and. Sylvain Chouinard. Article. Figures. Metrics. Save PDF. Cite. Rights & Permissions. Abstract. Background: The prevalence of sleep disturbances among patients with Parkinson’s disease (PD) is estimated to occur in 37% to 98% of patients.

    • Michel Panisset, Jean-Louis Stril, Manon Bélanger, Geneviève Lehoux, Donna Coffin, Sylvain Chouinard
    • 2016

  5. pubmed.ncbi.nlm.nih.gov › 28859150The real world effect of omalizumab add on therapy for ...

    31 de ago. de 2017 · PMID: 28859150. PMCID: PMC5578673. DOI: 10.1371/journal.pone.0183869. Abstract. Background: Omalizumab is a non-steroidal medication indicated for the treatment of poorly controlled moderate-to-severe allergic asthmatics. This observational study examines the "real world" effectiveness of omalizumab in this population.

    • Mohit Bhutani, William H. Yang, Jacques Hébert, Frederica de Takacsy, Jean-Louis Stril
    • 2017

  6. aacijournal.biomedcentral.com › articles › 10Proceedings of the Canadian Society of Allergy and Clinical ...

    29 de mar. de 2018 · Correspondence: Jean-Louis Stril. Allergy, Asthma & Clinical Immunology 2018, 14(Suppl 1):A26. Background: In Canada, it is estimated that asthma affects 8.5% of the total population. It is the leading cause of hospital admissions, the third leading cause of work loss, and results in 146,000 emergency room visits annually in the ...

  7. erj.ersjournals.com › content › 50Effectiveness of omalizumab in Canadian patients with ...

    Sara Chehab, William Yang, Remi Gagnon, Eliofotisti Psaradellis, Emmanouil Rampakakis, Jean-Louis Stril European Respiratory Journal Sep 2017, 50 (suppl 61) PA3542; DOI: 10.1183/1393003.congress-2017.PA3542